Flashcards in Antimycobacterials Deck (10):
Tb treatment drugs:
Inhibits RNAP, thereby stopping RNA synthesis.
-Inhibits synthesis of mycolic acids.
-Is a prodrug that is activated by KatG protein of the tubercle bacillus.
-Activated drug target is the enoyl-acyl carrier-protein reductase (InhA).
-All patients with Tb should receive this drug in combination with others.
-May produce peripheral neuritis.
-Watch for polymorphisms in N-acetyltransferase-2.
Ethambutol MOA and misc:
-Blocks mycobacterial cell wall synthesis by interfering with arabinosyltransferase.
-May produce optic neuritis, but not heptotoxicity.
-Blocks mycolic acid synthesis by inhibiting fatty acid synthase I.
-Important component of short-term combination therapy due to hepatotoxicity (can lead to severe hepatic damage).
Streptomycin class and use:
Aminoglycoside, reserved for only the most serious cases of Tb.
Which two drugs are for M. avium-intracellulare (MAC) treatment and prophylaxis?
Dapsone MOA, SEs, use:
MOA: Inhibits synthesis of folic acid
SE: Hemolytic anemia
Use: -Used in combination therapy (rifampin) for leprosy.
-Prophylaxis and treatment of Pneumocystis.
-Genetic polymorphisms in N-acetyltransferase.